Actinic Control SPF100 claims to help prevent actinic keratosis and non-melanoma skin cancer
Beiersdorf-owned dermocosmetics label Eucerin has grown its sun protection portfolio with the introduction of the brand’s first medical device.
Actinic Control SPF100 claims to help prevent actinic keratosis and non-melanoma skin cancer.
Actinic keratosis is the world’s most common precursor to non-melanoma skin cancer and can often be attributed to sun exposure.
According to Eucerin, an especially high sun protection factor combats sun-induced skin damage and provides people whose skin is already impaired with the necessary protection.
Actinic Control SPF100 prevents actinic keratosis and non-melanoma skin cancer while also providing skin that is sensitive to the sun with effective protection from sun-induced skin damage.
As such, it also serves as adjuvant treatment for patients already affected by actinic keratosis, says the brand.
“The highly effective combination of high UVA/UVB protection and broad-spectrum filters offers our consumers maximum sun protection,” said Gitta Neufang, Chief Innovation and Medical Officer at Eucerin.
“As intensive protection is important in particular for skin which is already damaged, we also tested its skin tolerance on patients with skin which is sensitive to the sun and with actinic keratosis.”
In addition to high sun protection and very good skin tolerance, the product has a fluid, non-greasy texture, which is light and readily absorbed, making it more pleasant for those affected to use.